Twitter

Link your Twitter Account to Market Wire News

When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.

Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / EXEL - Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors

EXEL - Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors

July, 24 2025 02:10 PM Exelixis Inc.

2025-07-24 14:10:46 ET

More on Exelixis, Ipsen

Exelixis: I Was Wrong To Be Too Cautious (Rating Upgrade)
Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment
Exelixis: A Notable Quarter
Exelixis cut to sector perform at RBC as cash flows fairly valued
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer

For further details see:

Ipsen granted EU nod for Exelixis-partnered cancer drug for neuroendocrine tumors

Stock Information

Company Name:	Exelixis Inc.
Stock Symbol:	EXEL
Market:	NASDAQ
Website:	exelixis.com

Get EXEL Alerts

News, Short Squeeze, Breakout and More Instantly...

Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.